GSA Capital Partners LLP increased its stake in the shares of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX – Get a rating) by 244.7% in Q1, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor held 16,420 shares of the specialty pharmaceutical company after purchasing an additional 11,657 shares during the quarter. GSA Capital Partners LLP owned 0.13% of Eagle Pharmaceuticals worth $813,000 at the end of the last quarter.
Other institutional investors and hedge funds have also been buying and selling shares of the company recently. Qube Research & Technologies Ltd acquired a new position in Eagle Pharmaceuticals during Q4 worth $499,000. Comerica Bank increased its position in Eagle Pharmaceuticals shares by 12.1% during the first quarter. Comerica Bank now owns 9,980 shares of the specialty pharmaceutical company worth $502,000 after acquiring an additional 1,080 shares last quarter. Alberta Investment Management Corp acquired a new stake in shares of Eagle Pharmaceuticals in Q4 valued at approximately $413,000. The South Dakota Investment Council increased its position in Eagle Pharmaceuticals shares by 2.7% in the fourth quarter. The South Dakota Investment Council now owns 112,534 shares of the specialty pharmaceutical company valued at $5,730,000 after purchasing an additional 2,930 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new equity stake in Eagle Pharmaceuticals in Q1 valued at approximately $386,000. 88.71% of the shares are held by institutional investors and hedge funds.
Eagle Pharmaceuticals sources 2.7%
EGRX opened at $37.81 on Monday. The company has a 50-day moving average price of $41.87 and a two-hundred-day moving average price of $45.45. The company has a quick ratio of 1.25, a current ratio of 1.78 and a leverage ratio of 0.12. The company has a market capitalization of $502.31 million, a PE ratio of 21.48 and a beta of 0.61. Eagle Pharmaceuticals, Inc. has a 52-week low of $33.72 and a 52-week high of $58.25.
Eagle Pharmaceuticals (NASDAQ: EGRX – Get a rating) last released its quarterly earnings data on Tuesday, August 9. The specialty pharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of $2.48 per ($3.22). The company posted revenue of $74.14 million in the quarter, compared to $108.13 million expected by analysts. Eagle Pharmaceuticals had a net margin of 8.37% and a return on equity of 11.18%. As a group, research analysts expect Eagle Pharmaceuticals, Inc. to post EPS of 2.88 for the current year.
Eagle Pharmaceuticals Profile
Eagle Pharmaceuticals, Inc, a pharmaceutical company, is focused on the development and commercialization of product candidates to treat central nervous system diseases or metabolic intensive care and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
Read more
Get news and reviews for Eagle Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
